{"entity":{"id":"nct07229599","kind":"trial","name":"A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of Furmonertinib and Carboplatin in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.","summary":"A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer is a phase 1/2 interventional study registered as NCT07229599 by Minghui Pharmaceutical (Hangzhou) Ltd, with 300 participants planned, started 2025-05-09 and due to reach its primary completion in 2029-05. Interventions recorded: MHB036C for Injection, MHB039A for Injection, Furmonertinib and Carboplatin.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07229599","url":"https://clinicaltrials.gov/study/NCT07229599"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["furmonertinib","carboplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07229599","phase":"1/2","setting":"A Phase I/II Clinical Study to Evaluate the Efficacy and Safety of MHB036C for Injection Combined With Other Anti-tumor Therapy in Patients With Advanced Lung Cancer","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","enrolled":300,"outcomes":[]},"route":"/trials/nct07229599/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"furmonertinib","kind":"drug","name":"Furmonertinib","route":"/drugs/furmonertinib/"},{"id":"mhb036c","kind":"drug","name":"MHB036C","route":"/drugs/mhb036c/"},{"id":"mhb039a","kind":"drug","name":"MHB039A","route":"/drugs/mhb039a/"}]}}